We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 605

Barbados launches biotech initiative designed to shorten R&D process

  • Shook Hardy & Bacon LLP
  • -
  • Barbados
  • -
  • December 16 2010

The Barbados government has recently launched two initiatives to attract biotech companies to the island nation

Biotechs launch stem cell research joint venture

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • April 21 2011

California-based BioTime Inc. and XenneX Inc. have announced a joint venture to “develop and commercialize a database of the thousands of cell lineages branching from embryonic stem cells and their molecular markers.”

Presidential bioethics panel to examine genome privacy

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • April 19 2012

The Presidential Commission for the Study of Bioethical Issues is seeking public comments “on the ethical issues raised by the ready availability of large-scale human genome sequence data, with regard to privacy and data access and the balancing of individual and societal interests.”

Comments sought on Class B medical device registration guidance in Singapore

  • Shook Hardy & Bacon LLP
  • -
  • Singapore
  • -
  • June 21 2012

Singapore’s Health Sciences Authority is requesting stakeholder comments by June 28, 2012, on new guidance pertaining to the registration of Class B medical devices

French company prevails in dispute with FDA over drug-classification ruling

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • October 3 2012

A federal court in the District of Columbia has determined that the Food and Drug Administration (FDA) erred when it classified a combination drug-device product as primarily a drug, thus subjecting its French manufacturer to more burdensome regulatory requirements

High investment interest in RNAi therapeutics

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 20 2014

With investments soaring in projects exploring therapeutic applications of RNA interference (RNAi), the field has apparently begun a significant

Researchers question accuracy of generic drug safety labeling

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • January 10 2013

According to Regenstrief Institute researchers, despite U.S. Food and Drug Administration (FDA) requirements that generic medications bear warnings

EU agency will reinstate Ranbaxy’s GMP certificate

  • Shook Hardy & Bacon LLP
  • -
  • European Union, India
  • -
  • June 12 2014

The European Medicines Agency (EMA) has reportedly concluded its investigation of alleged non-compliance with good manufacturing practice (GMP) at

New infringement lawsuit filed to protect BRCA1 and BRCA2 patents

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 26 2014

Myriad Genetics has brought a new infringement lawsuit against a company offering a next-generation sequencing test that analyzes the BRCA1 and BRCA2

EU medical device manufacturers address plan to change regulatory directives

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • February 8 2013

Eucomed, an organization that represents the interests of the European medical device industry, has issued a position paper that assesses a number of